Search

Your search keyword '"Rosenblat, Joshua D"' showing total 381 results
Start Over Author "Rosenblat, Joshua D" Publication Year Range Last 3 years
381 results on '"Rosenblat, Joshua D"'

2. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine

Author

Kwan, Angela T. H., Guo, Ziji, Ceban, Felicia, Le, Gia Han, Wong, Sabrina, Teopiz, Kayla M., Rhee, Taeho Greg, Ho, Roger, Di Vincenzo, Joshua D., Badulescu, Sebastian, Meshkat, Shakila, Cao, Bing, Rosenblat, Joshua D., d’Andrea, Giacomo, Dev, Donovan A., Phan, Lee, Subramaniapillai, Mehala, and McIntyre, Roger S.

Published
2024
Full Text
View/download PDF

14. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review

Author

Le, Gia Han, Wong, Sabrina, Badulescu, Sebastian, Au, Hezekiah, Di Vincenzo, Joshua D., Gill, Hartej, Phan, Lee, Rhee, Taeho Greg, Ho, Roger, Teopiz, Kayla M., Kwan, Angela T.H., Rosenblat, Joshua D., Mansur, Rodrigo B., and McIntyre, Roger S.

Published
2024
Full Text
View/download PDF

17. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin

Author

Rosenblat, Joshua D., Meshkat, Shakila, Doyle, Zoe, Kaczmarek, Erica, Brudner, Ryan M., Kratiuk, Kevin, Mansur, Rodrigo B., Schulz-Quach, Christian, Sethi, Rickinder, Abate, Amanda, Ali, Shaun, Bawks, Jordan, Blainey, Marc G., Brietzke, Elisa, Cronin, Victoria, Danilewitz, Jessica, Dhawan, Shalini, Di Fonzo, Anthony, Di Fonzo, Melissa, Drzadzewski, Pawel, Dunlop, William, Fiszter, Hajnalka, Gomes, Fabiano A., Grewal, Smrita, Leon-Carlyle, Marisa, McCallum, Marilyn, Mofidi, Niki, Offman, Hilary, Riva-Cambrin, Jeremy, Schmidt, Joel, Smolkin, Mark, Quinn, Joan M., Zumrova, Andrea, Marlborough, Michelle, and McIntyre, Roger S.

Published
2024
Full Text
View/download PDF

18. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data

Author

d'Andrea, Giacomo, Pettorruso, Mauro, Di Lorenzo, Giorgio, Rhee, Taeho Greg, Chiappini, Stefania, Carullo, Rosalba, Barlati, Stefano, Zanardi, Raffaella, Rosso, Gianluca, Di Nicola, Marco, Andriola, Ileana, Marcatili, Matteo, Clerici, Massimo, Dell'Osso, Bernardo Maria, Sensi, Stefano L., Mansur, Rodrigo B., Rosenblat, Joshua D., Martinotti, Giovanni, and McIntyre, Roger S.

Published
2024
Full Text
View/download PDF

19. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review

Author

Kwan, Angela T.H., Portnoff, Jacob S., Al-Kassimi, Khaled, Singh, Gurkaran, Hanafimosalman, Mehrshad, Tesla, Marija, Gharibi, Nima, Ni, Tiffany, Guo, Ziji, Sonfack, Davaine J.N., Martyniuk, Julia, Arfaie, Saman, Mashayekhi, Mohammad Sadegh, Mofatteh, Mohammad, Jeremian, Richie, Ho, Kevin, Moscote-Salazar, Luis Rafael, Lee, Ángel, Jawad, Muhammad Youshay, Ceban, Felicia, Teopiz, Kayla M., Mansur, Rodrigo B., Ho, Roger, Rosenblat, Joshua D., Cao, Bing, Rhee, Taeho Greg, and McIntyre, Roger S.

Published
2024
Full Text
View/download PDF

22. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)

Author

Pettorruso, Mauro, Guidotti, Roberto, d'Andrea, Giacomo, De Risio, Luisa, D'Andrea, Antea, Chiappini, Stefania, Carullo, Rosalba, Barlati, Stefano, Zanardi, Raffaella, Rosso, Gianluca, De Filippis, Sergio, Di Nicola, Marco, Andriola, Ileana, Marcatili, Matteo, Nicolò, Giuseppe, Martiadis, Vassilis, Bassetti, Roberta, Nucifora, Domenica, De Fazio, Pasquale, Rosenblat, Joshua D., Clerici, Massimo, Maria Dell'Osso, Bernardo, Vita, Antonio, Marzetti, Laura, Sensi, Stefano L., Di Lorenzo, Giorgio, McIntyre, Roger S., and Martinotti, Giovanni

Published
2023
Full Text
View/download PDF

32. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis

Author

Teopiz, Kayla M., primary, Kwan, Angela T. H., additional, Le, Gia Han, additional, Guo, Ziji, additional, Badulescu, Sebastian, additional, Ceban, Felicia, additional, Meshkat, Shakila, additional, Di Vincenzo, Joshua D., additional, d’Andrea, Giacomo, additional, Cao, Bing, additional, Ho, Roger, additional, Rhee, Taeho Greg, additional, Dev, Donovan A., additional, Phan, Lee, additional, Subramaniapillai, Mehala, additional, Mansur, Rodrigo B., additional, Rosenblat, Joshua D., additional, and McIntyre, Roger S., additional

Published
2024
Full Text
View/download PDF

33. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the united states food and drug administration adverse event reporting system (FAERS)

Author

McIntyre, Roger S., primary, Wong, Sabrina, additional, Kwan, Angela T.H., additional, Rhee, Taeho Greg, additional, Teopiz, Kayla M., additional, Ho, Roger, additional, Cao, Bing, additional, Mansur, Rodrigo B., additional, Rosenblat, Joshua D., additional, and Le, Gia Han, additional

Published
2024
Full Text
View/download PDF

35. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes

Author

Lam, Raymond W., primary, Kennedy, Sidney H., additional, Adams, Camelia, additional, Bahji, Anees, additional, Beaulieu, Serge, additional, Bhat, Venkat, additional, Blier, Pierre, additional, Blumberger, Daniel M., additional, Brietzke, Elisa, additional, Chakrabarty, Trisha, additional, Do, André, additional, Frey, Benicio N., additional, Giacobbe, Peter, additional, Gratzer, David, additional, Grigoriadis, Sophie, additional, Habert, Jeffrey, additional, Ishrat Husain, M., additional, Ismail, Zahinoor, additional, McGirr, Alexander, additional, McIntyre, Roger S., additional, Michalak, Erin E., additional, Müller, Daniel J., additional, Parikh, Sagar V., additional, Quilty, Lena S., additional, Ravindran, Arun V., additional, Ravindran, Nisha, additional, Renaud, Johanne, additional, Rosenblat, Joshua D., additional, Samaan, Zainab, additional, Saraf, Gayatri, additional, Schade, Kathryn, additional, Schaffer, Ayal, additional, Sinyor, Mark, additional, Soares, Claudio N., additional, Swainson, Jennifer, additional, Taylor, Valerie H., additional, Tourjman, Smadar V., additional, Uher, Rudolf, additional, van Ameringen, Michael, additional, Vazquez, Gustavo, additional, Vigod, Simone, additional, Voineskos, Daphne, additional, Yatham, Lakshmi N., additional, and Milev, Roumen V., additional

Published
2024
Full Text
View/download PDF

43. Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.

Author

Wong, Stanley, Yu, An Yi, Fabiano, Nicholas, Finkelstein, Ofer, Pasricha, Aryan, Jones, Brett D.M., Rosenblat, Joshua D., Blumberger, Daniel M., Mulsant, Benoit H., and Husain, M. Ishrat

Subjects
LSD (Drug), MENTAL health services, SUBSTANCE abuse, MEDICAL research, DATA extraction, PSILOCYBIN
Abstract

There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics remain limited. A comprehensive scoping review on the use of mescaline, ibogaine, ayahuasca, N,N-dimethyltryptamine (DMT), and lysergic acid diethylamide (LSD) in the treatment of mental and substance disorders was conducted. Independent reviewers screened titles, abstracts, and full texts and conducted data extraction. Seventy-seven studies met the inclusion criteria. There were 43 studies of LSD, 24 studies of ayahuasca, 5 studies of DMT, 5 studies of ibogaine, and 5 studies of mescaline. Commonly reported benefits included improved mood and anxiety symptoms, improved insight, reduced substance use, improved relationships, and decreased vegetative symptoms. Commonly reported adverse effects were psychological, neurological, physical, and gastrointestinal in nature. Serious adverse events (homicide and suicide) were reported in published studies of LSD. In conclusion, there is only low-level evidence to support the safety and efficacy of non-psilocybin serotonergic psychedelics in individuals with mental and substance use disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis.

Author

Gill, Hartej, Chen-Li, David C.J., Haikazian, Sipan, Seyedin, Sam, McIntyre, Roger S., Mansur, Rodrigo B., DiVincenzo, Joshua D., Phan, Lee, and Rosenblat, Joshua D.

Abstract

Converging evidence has suggested that treatment augmentation with a second-generation atypical antipsychotic (SGA) may improve treatment outcomes in major depressive disorder (MDD) patients after an incomplete response to a first-line antidepressant. Cariprazine is a recently approved SGA for MDD augmentation. Herein, we evaluate both continuous (ie, change in depressive symptom severity scores over time) and categorical (ie, remission and response rates) outcomes. Following a full-text review, four randomized controlled trials (RCTs) were included in our meta-analysis, while five studies were included for a qualitative review. Risk ratios (RRs) were calculated for all included randomized controlled studies to determine the relative response and remission rates of cariprazine compared to placebo augmentation. The RR for all-cause dropout was also determined as a proxy for overall acceptability. Two studies found a statistically significant treatment response using cariprazine augmentation. One study observed depressive symptom remission for cariprazine compared to placebo. Our random-effects model revealed moderate antidepressant effects of cariprazine, with a standardized mean difference (SMD) in Montgomery–Åsberg Depression Rating Scale (MADRS) scores of −1.79 (95% CI): −2.89, −0.69). Our pooled response RR and remission RR were calculated as 1.21 (95% CI: 1.05, 1.39, P =0.008) and 0.99 (95% CI: 0.84, 1.17, P =0.91), respectively. The RR for response was statistically significant (P <0.05). However, the RR for remission was not statistically significant. The findings from our meta-analysis include a variable magnitude of effects. Evidence suggests cariprazine may be an effective treatment for MDD; however, further results are needed to clarify this relation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis.

Author

Le, Gia Han, Kwan, Angela T.H., Guo, Ziji, Wong, Sabrina, Badulescu, Sebastian, Gill, Hartej, Teopiz, Kayla M., Meshkat, Shakila, Ceban, Felicia, Phan, Lee, Subramaniapillai, Mehala, Di Vincenzo, Joshua D., Rosenblat, Joshua D., Mansur, Rodrigo B., d'Andrea, Giacomo, Ho, Roger, Rhee, Taeho Greg, and McIntyre, Roger S.

Subjects
POST-acute COVID-19 syndrome, TRAIL Making Test, BLOOD sedimentation, COGNITIVE ability, BLOOD proteins
Abstract

Background: Individuals who have recovered from the acute stage of SARS-CoV-2 infection may be at risk of developing post-COVID-19 condition (PCC), characterised by a spectrum of persisting, non-specific, and functionally impairing symptoms across multiple organ systems. Obesity has been implicated as a risk factor for PCC, mediated by chronic systemic inflammation. The foregoing has also been separately reported to mediate cognitive dysfunction in PCC. Methods: This is a post-hoc analysis of a randomised, double-blinded, placebo-controlled clinical trial evaluating vortioxetine treatment for cognitive impairments in persons with PCC who received vortioxetine or placebo for eight weeks. This analysis comprises baseline data, examining the impact of BMI on cognitive functioning measured by the Digit Symbol Substitution Test (DSST) and Trails Making Tests (TMT)-A/B, as well as inflammation, via serum c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Results: Complete data from 70 participants were statistically analysed and adjusted for age and sex. BMI was negatively correlated with performance on the DSST (β = −0.003, p = 0.047), TMT-A (β = −0.006, p = 0.025), and TMT-B (β = −0.006, p = 0.002). BMI was positively correlated with serum CRP (unstandardized β = 0.193, standardized β = 0.612, p < 0.001) and ESR (β = 0.039, p < 0.001) levels. Conclusion: We observed a significant negative correlation between BMI and cognitive functioning, and a significant positive correlation between BMI and inflammation in persons with PCC, suggesting a bidirectional interplay between BMI, PCC, and cognitive function; individuals with an elevated BMI may be at a greater risk of developing PCC and/or presenting with greater cognitive deficits mediated by chronic systemic inflammation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Prescribed psychostimulants and other pro‐cognitive medications in bipolar disorder: A systematic review and meta‐analysis of recurrence of manic symptoms.

Author

Chiorean, Andreea, Jones, Brett D. M., Murong, Mijia, Gonzalez‐Torres, Christina, Kloiber, Stefan, Ortiz, Abigail, Rosenblat, Joshua D., Mulsant, Benoit H., and Husain, M. Ishrat

Subjects
BIPOLAR disorder, STIMULANTS, MEDICAL personnel, HYPOMANIA, MANIA
Abstract

Objectives: Clinicians are often hesitant to prescribe psychostimulants in bipolar disorder (BD) due to concerns of inducing (hypo)mania, despite limited published evidence on associations between prescribed psychostimulant use and recurrence of mood episodes in BD. The current systematic review and meta‐analysis evaluated the emergence of (hypo)manic symptoms in patients with BD receiving prescribed psychostimulants or other pro‐cognitive medications in euthymic or depressive states. Methods: A systematic search was performed of MEDLINE, Embase, and PsychINFO from inception to April 5, 2023 and search of Clinicaltrials.gov and Clinicaltrialsregister.eu for unpublished data. References of included studies were hand‐searched. Randomized trials and prospective longitudinal studies that evaluated psychostimulants and non‐stimulant medications recommended for the treatment of ADHD by the Canadian ADHD practice guidelines were included. The review was reported in line with PRISMA guidelines and was preregistered on PROSPERO (CRD42022358588). Results: After screening 414 unique records, we included 27 studies, of which five reported data that was quantitatively synthesized (n = 1653). The use of psychostimulants in BD was not associated with increased scores on the Young Mania Rating Scale in patients who were in a euthymic or depressed state (SMD IV −0.17; 95% CI, −0.40 to 0.06) compared to placebo. There was a high degree of study‐level heterogeneity (I2 = 80%). A qualitative synthesis of studies revealed a limited risk of medication‐induced manic symptoms. Conclusions: Our review provides preliminary evidence to suggest psychostimulants and non‐stimulant ADHD medications have a limited risk of precipitating (hypo)mania symptoms. More extensive studies evaluating the safety and efficacy of these medications are warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results